机构

• 上海药物研究所 [13]
• 地理科学与资源研究所 [1]

采集方式

• OAI收割 [14]

内容类型

• 期刊论文 [14]

发表日期

• 2024 [1]
• 2023 [1]
• 2022 [1]
• 2021 [2]
• 2020 [1]
• 2019 [4]
• 更多

学科主题

筛选

浏览/检索结果: 共14条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Flowering in the Northern Hemisphere is delayed by frost after leaf-out 期刊论文  OAI收割 NATURE COMMUNICATIONS, 2024, 卷号: 15, 期号: 1, 页码: 11 作者:  Qiu, Haoyu;  Yan, Qin;  Yang, Yuchuan;  Huang, Xu;  Wang, Jinmei   |  收藏  |  浏览/下载：7/0  |  提交时间：2024/12/30 Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 卷号: 13, 期号: 1, 页码: 161-+ 作者:  Li, Yongpeng;  Li, Lin;  Fu, Haoyu;  Yao, Qing;  Wang, Lei   |  收藏  |  浏览/下载：19/0  |  提交时间：2023/10/17 Antibody-drug conjugate  DS-8201  PARP  ATR  synergy  DNA damage   Trastuzumab in combination with PEGylated interferon-alpha 1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 卷号: 12, 期号: 2, 页码: 549-561 作者:  Xu, Piaopiao;  Chen, Xiangling;  Xu, Yongping;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：173/0  |  提交时间：2022/06/15 Trastuzumab  PEGylated IFN-alpha 1b  ADCC  HER2-positive cancer  synergistic effect   Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文  OAI收割 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu   |  收藏  |  浏览/下载：65/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 卷号: 11, 期号: 4, 页码: 1632-1645 作者:  Wang, Lei;  Zhu, Xi;  Li, Lili;  Li, Lin;  Fu, Li   |  收藏  |  浏览/下载：26/0  |  提交时间：2021/06/11 PARP  DNA damage  hematologic toxicity  beta-glucuronidase  tumor selectivity   YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer 期刊论文  OAI收割 BRITISH JOURNAL OF CANCER, 2020, 页码: 12 作者:  Wang, Lei;  Wang, Quanren;  Xu, Piaopiao;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：20/0  |  提交时间：2020/12/24 SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文  OAI收割 CANCER SCIENCE, 2019, 页码: 11 作者:  Tong, Mengya;  Gao, Mingzhao;  Xu, Yongping;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：63/0  |  提交时间：2020/07/01 AZD9291  c-Met ADC  c-Met overexpression  resistance  SHR-A1403   Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants 期刊论文  OAI收割 CANCER SCIENCE, 2019, 页码: 9 作者:  Gao, Mingzhao;  Zhu, Hongmei;  Fu, Li;  Li, Yun;  Bao, Xubin   |  收藏  |  浏览/下载：42/0  |  提交时间：2020/07/01 AG-221  IDH2  leukemia  R140Q  R172K   Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models 期刊论文  OAI收割 CANCER SCIENCE, 2019, 卷号: 110, 期号: 4, 页码: 1420-1430 作者:  Long, Fei;  He, Ye;  Fu, Haoyu;  Li, Yun;  Bao, Xubin   |  收藏  |  浏览/下载：38/0  |  提交时间：2020/07/01 breast cancer  CDK 4/6  drug resistance  palbociclib  SHR6390   Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials 期刊论文  OAI收割 CANCER SCIENCE, 2019, 卷号: 110, 期号: 3, 页码: 1064-1075 作者:  Wang, Lei;  Yang, Changyong;  Xie, Chengying;  Jiang, Jiahua;  Gao, Mingzhao   |  收藏  |  浏览/下载：26/0  |  提交时间：2020/07/01 antitumor activity  fluzoparib  pharmacokinetics  poly(ADP-ribose) polymerase  toxicity